Syndax Pharmaceuticals
SNDX
72 hedge funds and large institutions have $244M invested in Syndax Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 15 closing their positions.
62% more capital invested
Capital invested by funds: $150M → $244M (+$94M)
60% more call options, than puts
Call options by funds: $635K | Put options by funds: $397K
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.88% less ownership
Funds ownership: 70.41% → 69.53% (-0.88%)
10% less funds holding
Funds holding: 80 → 72 (-8)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.18M |
| 2 |
6CM
683 Capital Management
New York
|
+$3.01M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.36M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.84M |
| 5 |
BlackRock
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.65M |
| 2 |
Millennium Management
New York
|
-$1.86M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$1.79M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.51M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$613K |
SNDX Hedge Fund Activity: Q1 2018 in Review
72 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2018, worth a combined $244M — up 62% from $150M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SNDX and 7 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 28 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.18M. The largest seller was Jennison Associates, exiting entirely with an estimated $4.65M sold.
- 72 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2018, down from 80 in Q4 2017.
- Funds reported $244M of Syndax Pharmaceuticals stock for Q1 2018, up 62% quarter-over-quarter.
- 7 funds opened new Syndax Pharmaceuticals positions in Q1 2018 and 15 closed out, a net change of -8 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2018 was Point72 Asset Management, an estimated $3.18M added.
- The largest Syndax Pharmaceuticals seller in Q1 2018 was Jennison Associates, an estimated $4.65M sold.
Based on aggregated 13F filings for Q1 2018.